PT  - JOURNAL ARTICLE
AU  - Toby M. Maher
AU  - Ulrich Costabel
AU  - Marilyn K. Glassberg
AU  - Yasuhiro Kondoh
AU  - Takashi Ogura
AU  - Mary Beth Scholand
AU  - David Kardatzke
AU  - Monet Howard
AU  - Julie Olsson
AU  - Margaret Neighbors
AU  - Paula Belloni
AU  - Jeffrey J. Swigris
TI  - Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis
AID  - 10.1183/13993003.02442-2019
DP  - 2021 Feb 01
TA  - European Respiratory Journal
PG  - 1902442
VI  - 57
IP  - 2
4099  - http://erj.ersjournals.com/content/57/2/1902442.short
4100  - http://erj.ersjournals.com/content/57/2/1902442.full
SO  - Eur Respir J2021 Feb 01; 57
AB  - This phase 2, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of lebrikizumab, an interleukin (IL)-13 monoclonal antibody, alone or with background pirfenidone therapy, in patients with idiopathic pulmonary fibrosis (IPF).Patients with IPF aged ≥40 years with forced vital capacity (FVC) of 40%–100% predicted and diffusing capacity for carbon monoxide of 25%–90% predicted and who were treatment-naïve (cohort A) or receiving pirfenidone (2403 mg·day−1; cohort B) were randomised 1:1 to receive lebrikizumab 250 mg or placebo subcutaneously every 4 weeks. The primary endpoint was annualised rate of FVC % predicted decline over 52 weeks.In cohort A, 154 patients were randomised to receive lebrikizumab (n=78) or placebo (n=76). In cohort B, 351 patients receiving pirfenidone were randomised to receive lebrikizumab (n=174) or placebo (n=177). Baseline demographics were balanced across treatment arms in both cohorts. The primary endpoint (annualised rate of FVC % predicted decline) was not met in cohort A (lebrikizumab versus placebo, −5.2% versus −6.2%; p=0.456) or cohort B (lebrikizumab versus placebo, −5.5% versus −6.0%; p=0.557). In cohort B, a non-statistically significant imbalance in mortality favouring combination therapy was observed (hazard ratio 0.42 (95% CI 0.17–1.04)). Pharmacodynamic biomarkers indicated lebrikizumab activity. The safety profile was consistent with that in previous studies of lebrikizumab and pirfenidone as monotherapies.Lebrikizumab alone or with pirfenidone was not associated with reduced FVC % predicted decline over 52 weeks despite evidence of pharmacodynamic activity. Lebrikizumab was well tolerated with a favourable safety profile. These findings suggest that blocking IL-13 may not be sufficient to achieve a lung function benefit in patients with IPF.This phase 2 RCT found no benefit in FVC decline over 52 weeks in IPF patients for lebrikizumab versus placebo as monotherapy (n=78 versus 76) or in combination with pirfenidone (n=174 versus 177); pirfenidone therapy was consistent with previous results https://bit.ly/313NVR8